SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Success Way and freedom. Business woman walking to the exit through an open door.
NextGen
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
February 18, 2025
 · 
2 min read
 · 
Annalee Armstrong
Pictured: White House/
FDA
‘No Job Security’ at FDA as Trump Team Seeks to Dismantle Workforce: Updated
The hammer came down on an unspecified number of FDA employees this weekend, days after Robert F. Kennedy Jr. was confirmed as HHS Secretary.
February 17, 2025
 · 
6 min read
 · 
Heather McKenzie
Close-Up Of Syringe With Bottles Against Blue Background
Vaccines
FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat
The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health and Human Services.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Employee competency assessment. Collage of hands holding king and a pawn. Succession planning.
Cancer
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Blue Sanofi sign on building in Germany at night
Approvals
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
February 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times
Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.
February 17, 2025
 · 
1 min read
 · 
Lori Ellis
x-ray wrist muscle pain in gray background
Opinion
Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1
With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma.
February 17, 2025
 · 
4 min read
 · 
Jia Jie Chen
Mushrooms and mental health as Psychedelic drug or psychedelics hallucinogenic drugs and hallucinogens representing medicine for brain disorders in a 3D illustration style.
Psychedelics
Psychedelics Space Regroups as RFK Jr. Signals Support
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a recent approval and positive data are generating new momentum, which experts expect to continue throughout 2025 and 2026.
February 17, 2025
 · 
5 min read
 · 
Heather McKenzie
Businessman climbed the clouds to see the distance
Immunology and Inflammation
I&I Investment Ramps Up With Novel Targets and Boundless Opportunity
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.
February 17, 2025
 · 
5 min read
 · 
Kate Goodwin
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS